AR117708A1 - Procedimiento in vitro para la detección de disbiosis intestinal aviar - Google Patents

Procedimiento in vitro para la detección de disbiosis intestinal aviar

Info

Publication number
AR117708A1
AR117708A1 ARP190103688A ARP190103688A AR117708A1 AR 117708 A1 AR117708 A1 AR 117708A1 AR P190103688 A ARP190103688 A AR P190103688A AR P190103688 A ARP190103688 A AR P190103688A AR 117708 A1 AR117708 A1 AR 117708A1
Authority
AR
Argentina
Prior art keywords
detection
intestinal dysbiosis
avian
vitro procedure
avian intestinal
Prior art date
Application number
ARP190103688A
Other languages
English (en)
Inventor
Lynn Vanhaecke
Meulebroek Lieven Van
Ducatelle Richard Prof
Van Immerseel Filip Prof
Goossens Evy Dr
Hark Sarah Dr
Flgel Monika Dr
Pelzer Stefan Dr
Original Assignee
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations Gmbh filed Critical Evonik Operations Gmbh
Publication of AR117708A1 publication Critical patent/AR117708A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente se refiere a un procedimiento in vitro para la detección de disbiosis intestinal aviar, el procedimiento comprende la determinación de la presencia y/o el nivel de isoleucil-arginina (C₁₂H₂₅O₃N₅) o isómeros de la misma en material de muestra aviar, en el que la presencia y/o un aumento del nivel de isoleucil-arginina (C₁₂H₂₅O₃N₅) o isómeros de la misma en comparación con un control no afectado es indicativo de disbiosis intestinal aviar.
ARP190103688A 2018-12-14 2019-12-16 Procedimiento in vitro para la detección de disbiosis intestinal aviar AR117708A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18212599 2018-12-14

Publications (1)

Publication Number Publication Date
AR117708A1 true AR117708A1 (es) 2021-08-25

Family

ID=64745890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103688A AR117708A1 (es) 2018-12-14 2019-12-16 Procedimiento in vitro para la detección de disbiosis intestinal aviar

Country Status (14)

Country Link
US (1) US20220050115A1 (es)
EP (1) EP3894863B1 (es)
KR (1) KR20210104770A (es)
CN (1) CN113167803B (es)
AR (1) AR117708A1 (es)
BR (1) BR112021011158A2 (es)
CA (1) CA3122457A1 (es)
DK (1) DK3894863T3 (es)
ES (1) ES2938227T3 (es)
HU (1) HUE060993T2 (es)
MX (1) MX2021006917A (es)
PL (1) PL3894863T3 (es)
WO (1) WO2020120376A1 (es)
ZA (1) ZA202104738B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12031991B2 (en) 2018-03-02 2024-07-09 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
WO2022117382A1 (en) * 2020-12-04 2022-06-09 Evonik Operations Gmbh A method for classifying the gut inflammation status in avian species

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616561C (en) * 2005-07-25 2018-12-18 Avianax, Llc Therapeutic goose antibodies for treatment and prophylaxis of transmittable viral diseases
EP2776829A4 (en) * 2011-11-08 2015-05-27 Univ Texas METHODS AND USES OF METABOLIC PROFILING FOR DIFFICULT CLOSTRIDIUM INFECTION (CDI)
EP2909335B1 (en) * 2012-10-17 2018-05-30 Institut National de la Recherche Agronomique Prognostic of diet impact on obesity-related co-morbidities
CN103431198B (zh) * 2013-09-06 2014-12-10 山东凤祥股份有限公司 一种禽类饲料添加剂及禽类饲料
CN104431644A (zh) * 2015-01-13 2015-03-25 四川农业大学 一种改善断奶仔猪生长性能和肠道健康的氨基酸添加剂
AU2016215209A1 (en) * 2015-02-06 2017-07-20 Western University Of Health Sciences Probiotic compositions and methods of use
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
US10632157B2 (en) * 2016-04-15 2020-04-28 Ascus Biosciences, Inc. Microbial compositions and methods of use for improving fowl production
WO2017053544A1 (en) * 2015-09-22 2017-03-30 Mayo Foundation For Medical Education And Research Methods and materials for using biomarkers which predict susceptibility to clostridium difficile infection
WO2018171555A1 (en) * 2017-03-20 2018-09-27 Crown Bioscience Inc. (Taicang) Use of gut microbiota composition in immunotherapy
WO2018206690A1 (en) * 2017-05-12 2018-11-15 Evonik Degussa Gmbh Method for detecting c. perfringens induced diseases in animals

Also Published As

Publication number Publication date
CA3122457A1 (en) 2020-06-18
EP3894863B1 (en) 2022-11-23
KR20210104770A (ko) 2021-08-25
MX2021006917A (es) 2021-07-07
HUE060993T2 (hu) 2023-04-28
EP3894863A1 (en) 2021-10-20
PL3894863T3 (pl) 2023-03-20
ZA202104738B (en) 2022-12-21
DK3894863T3 (en) 2023-02-20
WO2020120376A1 (en) 2020-06-18
CN113167803A (zh) 2021-07-23
BR112021011158A2 (pt) 2021-08-31
ES2938227T3 (es) 2023-04-05
CN113167803B (zh) 2024-06-07
US20220050115A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
CL2019002438A1 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
CL2020002342A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
CL2017001212A1 (es) Composiciones, dispositivos y método para pruebas de sensibilidad de síndrome del intestino irritable
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
ES2811835T3 (es) Procedimiento para determinar el riesgo de toxicidad por 5-fluorouracilo
CO2019002607A2 (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto
BR112018071600A2 (pt) métodos, composições e usos relacionados aos mesmos
AR117708A1 (es) Procedimiento in vitro para la detección de disbiosis intestinal aviar
CO2019008675A2 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
CO2021000092A2 (es) Anticuerpos que comprenden un polipéptido insertado en la región 3 del marco
BR112018071601A2 (pt) métodos, composições e usos relacionados aos mesmos
BR112017005022A2 (pt) câmara de película com volume de medição para a detecção de grandes vazamentos e método para testar um objeto de teste
BR112018071618A2 (pt) métodos, composições e usos relacionados aos mesmos
BR112018071568A2 (pt) métodos, composições e usos relacionados aos mesmos
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
BR112017006593A2 (pt) método para detectar câncer de ovário
CL2017000563A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.
BR112016017926A2 (pt) ensaio para detectar periostina humana
AR108890A1 (es) Inhibidores de la entrada del cmvh
CO2020003949A2 (es) Fideo de cristal con almidón de chícharo de baja estabilidad
UY36795A (es) Procedimientos de purificacion de un virus producido in vitro y ensayo de eliminacion del virus